State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer
American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)
DOI: 10.1200/edbk-25-473636 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Wassim Abida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Precision Medicine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling methods applied in the clinic, namely, next-generation sequencing and advanced positron emission tomography (PET) imaging, has allowed for the development of biomarker-driven therapeutics including anti–PD-L1 therapy for microsatellite instability-high or tumor mutation burden-high disease, poly(ADP-ribose) polymerase (PARP) inhibitors for patients with DNA damage repair mutations, and lutetium 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) for patients with prostate-specific membrane antigen (PSMA) PET-avid disease. While these targeted therapies have improved outcomes, there is an opportunity to refine biomarkers to optimize patient selection, understand resistance, and develop novel combination strategies. In addition, studies in the laboratory and in patient-derived samples have shown that a subset of mCRPC tumors lose expression of common prostate cancer markers such as prostate-specific antigen and PSMA because of lineage plasticity and the development of non–androgen receptor (AR)-driven disease. Non–AR-driven prostate cancer has been associated with aggressive behavior and poor prognosis, including in some cases histologic transformation to a poorly differentiated neuroendocrine prostate cancer (NEPC). The clinical management of NEPC typically follows the treatment paradigm for small cell lung cancer and increasingly relies on genomic and phenotypic characterization of disease, including loss of tumor suppressors and expression of cell surface markers such as DLL3. Therefore, both genomic subtyping and phenotypic subtyping are important to consider and can guide the clinical management of patients with advanced prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA.
ORCID-Profile: Wassim Abida
Zitieren
APA
Abida, W., Beltran, H., & Raychaudhuri, R. (2025). State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-473636
Vancouver
Abida W, Beltran H, Raychaudhuri R. State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-473636
BibTeX
@article{Abida2025,
author = {Abida, Wassim and Beltran, Himisha and Raychaudhuri, Ruben},
title = {State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer},
journal = {American Society of Clinical Oncology Educational Book},
year = {2025},
volume = {45},
number = {3},
doi = {10.1200/edbk-25-473636}
}
EUVIMED